Innovative Pharmaceutical Biotech (HKSE:00399) COGS-to-Revenue : 0.90 (As of Sep. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech COGS-to-Revenue?

Innovative Pharmaceutical Biotech's Cost of Goods Sold for the six months ended in Sep. 2023 was HK$3.35 Mil. Its Revenue for the six months ended in Sep. 2023 was HK$3.73 Mil.

Innovative Pharmaceutical Biotech's COGS to Revenue for the six months ended in Sep. 2023 was 0.90.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Innovative Pharmaceutical Biotech's Gross Margin % for the six months ended in Sep. 2023 was 10.20%.

Innovative Pharmaceutical Biotech COGS-to-Revenue Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech COGS-to-Revenue Chart

Innovative Pharmaceutical Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

Get a 7-Day Free Trial

0.91

0.89

0.91

0.89

Innovative Pharmaceutical Biotech Semi-Annual Data
	Dec13	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															0.89	0.93	0.90	0.89	0.90

Innovative Pharmaceutical Biotech COGS-to-Revenue Calculation

Innovative Pharmaceutical Biotech's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	7.217	/	8.075
	=	0.89

Innovative Pharmaceutical Biotech's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.347	/	3.727
	=	0.90

Innovative Pharmaceutical Biotech (HKSE:00399) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Innovative Pharmaceutical Biotech's Gross Margin % for the six months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	3.347 / 3.727
	=	10.20 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Innovative Pharmaceutical Biotech COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative Pharmaceutical Biotech (HKSE:00399) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

168-200 Connaught Road Central, Unit No. 2111, 21st Floor, Sheung Wan, West Tower Shun Tak Centre, Hong Kong, HKG

Website

http://www.ipb.asia

Innovative Pharmaceutical Biotech Ltd is focused on developing an insulin product that could be administered orally. It has two primary segments of business: the research and development of pharmaceutical products and the trading of beauty products. It generates maximum revenue from trading in the beauty products segment.

Innovative Pharmaceutical Biotech (HKSE:00399) Headlines

No Headlines